OrganOx, a British developer of technologies to maintain organs for transplant, raised $142m in primary and secondary funding ...

OrganOx's metra normothermic machine perfusion platform gained approval in Australia, Europe, Canada, and the US.

The oversubscribed round was led by new investor HealthQuest Capital with support from existing OrganOx investors BGF and Lauxera Capital Partners, along with additional new investors Sofina ...

OrganOx announced today that it completed a $142 million primary and secondary equity financing to accelerate growth opportunities.

New investors Amzak Health and HealthQuest Capital participated in the funding round, while existing investors including Johnson & Johnson Innovation-JJDC Inc. and Lumira Ventures invested as well.

We apologize, but this video has failed to load. “Organ disease and failure represent a large unmet need in healthcare, and we are excited to partner with HealthQuest Capital and the outstanding ...

Financing strengthens OrganOx to expand its leadership position in organ technologyOXFORD, United Kingdom and MADISON, N.J., Feb. 24, 2025., a leading organ medical technology company, successfully co ...